ACADIA Pharmaceuticals (GB:0A4W)

ACADIA Pharmaceuticals (0A4W) Stock Price & Analysis


0A4W Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$12.27 - $27.71
Previous Close$18.38
Average Volume (3M)1.15K
Market Cap
Enterprise Value$2.66B
Total Cash (Recent Filing)$416.82M
Total Debt (Recent Filing)$62.00M
Price to Earnings (P/E)N/A
May 03, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
Shares Outstanding162,230,184
10 Day Avg. Volume158
30 Day Avg. Volume1,147
Standard Deviation0.13
Financial Highlights & Ratios
Price to Book (P/B)7.39
Price to Sales (P/S)14.69
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-25.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.15
Enterprise Value/Gross Profit5.25
Enterprise Value/Ebitda-12.02
Price Target Upside24.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20




What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was $12.27 and its highest was $27.70 in the past 12 months.
    What is ACADIA Pharmaceuticals’s market cap?
    Currently, no data Available
    When is ACADIA Pharmaceuticals’s upcoming earnings report date?
    ACADIA Pharmaceuticals’s upcoming earnings report date is May 03, 2023 which is in 36 days.
      How were ACADIA Pharmaceuticals’s earnings last quarter?
      ACADIA Pharmaceuticals released its earnings results on Feb 27, 2023. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.247 by -$0.013.
        Is ACADIA Pharmaceuticals overvalued?
        According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does ACADIA Pharmaceuticals pay dividends?
          ACADIA Pharmaceuticals does not currently pay dividends.
          What is ACADIA Pharmaceuticals’s EPS estimate?
          ACADIA Pharmaceuticals’s EPS estimate is -$0.22.
            How many shares outstanding does ACADIA Pharmaceuticals have?
            Currently, no data Available
            What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
            ACADIA Pharmaceuticals reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.247. Following the earnings report the stock price went up 12.965%.
              Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
              Among the largest hedge funds holding ACADIA Pharmaceuticals’s share is Baker Bros Advisors LP. It holds ACADIA Pharmaceuticals’s shares valued at 667M.


                ACADIA Pharmaceuticals Stock Smart Score

                The ACADIA Pharmaceuticals Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                ACADIA Pharmaceuticals

                ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                PTC Therapeutics
                Blueprint Medicines
                IVERIC bio
                Ultragenyx Pharmaceutical

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis